Sunitinib is a small molecule inhibitor of receptor tyrosine kinases, including FLK1 (Ki = 9 nM), PDGFRbeta (Ki = 8 nM), and FLT3. It is at least 10-fold selective for FLK1 and PDGFRbeta over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src. Sunitinib inhibits VEGF-dependent...

Description: Sunitinib Malate (Sunitinib) is an indolinone-based tyrosine kinase inhibitor. It blocks the tyrosine kinase activities of VEGFR2, PDGFRbeta (IC50: 80/2 nM), and c-kit. Target: VEGFR, c-Kit, Autophagy, FLT, PDGFR, IRE1, Apoptosis, Mitophagy. Smiles:...

A multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Sunitinib and its active metabolite (SU012662) are selective inhibitors of multiple receptor tyrosine kinases, including platelet-derived growth factor receptor and vascular endothelial growth factor receptor, that are associated with tumor...

Potent ATP-competitive and cell permeable multi-targeted receptor tyrosine kinase (RTK) inhibitor targeting VEGFR and PDGFR-beta. Inhibits FLK1 (Ki=9nM), PDGFRbeta (Ki=8nM) and FLT3. It is at least 10-fold selective for FLK1 and PDGFRbeta over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met,...